| Publisher |
Company of Biologists |
| Agreement ID | compbio2022bibsam |
| Agreement labeling | Company of Biologists Read and Publish |
| Has the agreement been fully disclosed and published? | Yes |
| URL | https://urn.kb.se/resolve?urn=urn:nbn:se:kb:publ-672 |
| Agreement period | 01/01/2022 – 12/31/2024 |
| Consortia / Institution | Bibsam Consortium |
| Country | Sweden |
| SIZE
Approximate range of annual corresponding author publications |
20 |
| COSTS
How do the costs of the agreement relate to previous subscription-only agreements with the publisher? |
Agreement costs within the range of the previous spending level |
| FINANCIAL SHIFT
Transformative agreements vary by their transformative mechanisms, meaning the way in which financing is shifted from the subscription side to open access publishing. What are the characteristics of this agreement to this regard? |
Subscriptions partly converted to OA publishing fees |
| RISK SHARING
How do entitlements for open access publishing correlate to the anticipated article output? Which mechanisms for risk sharing have been agreed in cases of exceeding or not reaching the number of OA publishing entitlements? |
Open access published output is unlimited |
| OA COVERAGE
Are all journals relevant to your affiliated authors (in which you expect them to publish) eligible for OA publishing under the agreement? |
Yes |
| Are fully open access journals covered by the agreement? | Yes |
| OA LICENSE | CC-BY mandatory |
| ARTICLE TYPES |
Original research articles |
| ACCESS COSTS
What is the approximate share of access related costs of the overall agreement? |
More than 50% |
| ACCESS COVERAGE
Are all read relevant journals covered by the agreement? |
Yes |
| PERPETUAL ACCESS RIGHTS | Yes |
| WORKFLOW ASSESSMENT | Too early to assess |
| OVERALL ASSESSMENT AND COMMENTS | The agreement allows unlimited access to and open access publishing of research articles in all the society’s journals. The price is based on current spend and fixed for the first two years of the agreement, with a modest price increase in year three. |
| Request contact to the licensee | contact@esac-initiative.org |